Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 26 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

35%

9 trials in Phase 3/4

Results Transparency

61%

14 of 23 completed trials have results

Key Signals

2 recruiting14 with results

Enrollment Performance

Analytics

Phase 2

12(48.0%)

Phase 3

7(28.0%)

Phase 1

3(12.0%)

Phase 4

2(8.0%)

N/A

1(4.0%)

25Total

Phase 2(12)

Phase 3(7)

Phase 1(3)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT06300450Not ApplicableRecruiting

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

Role: collaborator

NCT05694260Phase 2Completed

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Role: lead

NCT06021951Phase 4Completed

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Role: lead

NCT05103254Recruiting

Bempedoic Acid Pregnancy Surveillance Program

Role: lead

NCT02993406Phase 3Completed

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Role: lead

NCT02178098Phase 2Completed

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Role: lead

NCT01751984Phase 2Completed

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Role: lead

NCT05263778Phase 4Unknown

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Role: collaborator

NCT01262638Phase 2Completed

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Role: lead

NCT03067441Phase 3Completed

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Role: lead

NCT03001076Phase 3Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Role: lead

NCT02666664Phase 3Completed

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Role: lead

NCT02991118Phase 3Completed

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Role: lead

NCT03531905Phase 2Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Role: lead

NCT03337308Phase 3Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Role: lead

NCT03193047Phase 2Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Role: lead

NCT03051100Phase 2Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Role: lead

NCT02988115Phase 3Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Role: lead

NCT02072161Phase 2Completed

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Role: lead

NCT01941836Phase 2Completed

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Role: lead